EN
中文
EN
Who We Are
Newsroom
Innovation
Products
Investor Relations
Careers
Contact Us
Information Disclosure
Home
>
Investor Relations
>
Information Disclosure
H Share
VOLUNTARY ANNOUNCEMENT - CLINICAL RESEARCH RESULTS OF EVALUATION OF THE SAFETY AND IMMUNOGENICITY OF TWO TYPES OF RECOMBINANT COVID-19 VACCINES IN A POPULATION AGED 6 TO 17 YEARS
VOLUNTARY ANNOUNCEMENT - CLINICAL RESEARCH RESULTS OF A CLINICAL TRIAL OF BIVALENT RECOMBINANT COVID-19 VACCINE (ADENOVIRUS TYPE 5 VECTOR) FOR INHALATION IN ADULTS
VOLUNTARY ANNOUNCEMENT - CLINICAL RESEARCH RESULTS OF A RANDOMIZED, OPEN-LABEL AND PARALLEL-CONTROLLED CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF HETEROLOGOUS PRIME-BOOST IMMUNIZATION
POLL RESULTS OF THE 2022 FIRST EXTRAORDINARY GENERAL MEETING
DISCLOSEABLE TRANSACTION PURCHASE OF STRUCTURED DEPOSIT
DISCLOSEABLE TRANSACTION PURCHASE OF STRUCTURED DEPOSIT
VOLUNTARY ANNOUNCEMENT - RECOMBINANT COVID-19 VACCINE (ADENOVIRUS TYPE 5 VECTOR) AND RECOMBINANT COVID-19 VACCINE (ADENOVIRUS TYPE 5 VECTOR) FOR INHALATION RECOMMENDED AS THE SECOND BOOSTER DOSE
Notification Letter and Request Form to Non-registered Shareholders
CIRCULAR OF THE 2022 FIRST EXTRAORDINARY GENERAL MEETING
NOTICE OF THE 2022 FIRST EXTRAORDINARY GENERAL MEETING
1
20
21
22
23
24
52
津公网安备12011602300399
